Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 450

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 19
Chunk 450
---
ad for the filgotinib development amount to €26.0 million in 2024 compared to €429.4 million in 2023 and €174.4 million in 2022. The sale of the Jyseleca® business to Alfasigma on January 31, 2024 led to the full recognition in revenue in 2024 of the remaining deferred income related to filgotinib.​
We refer to note 2 “Summary of significant transactions” for a general description of our collaboration with Gilead. 
All filgotinib development expenses and all remaining G&A and S&M expenses relating to Jyseleca® are recharged to Alfasigma, which explains the decrease in those expenses.
Other operating income includes €52.5 million related to the gain on the sale of the Jyseleca® business to Alfasigma in 2024.

F-33

III Cash flow used in discontinued operations
​

                      ​                         ​   ​      ​       ​   ​       ​       ​   ​       ​    
--------------------------------------------------------------------------------------------------------
​                                               2024               2023                2022             
​                                               ​   (Euro,                                              
                                                    in thousands)                                       
Net cash flow used in operating activities      ​   €   (36,367)   ​   €   (175,627)   ​   €   (191,095)
Net cash flow used in investing activities      ​   ​    (8,949)   ​   ​       (105)   ​   ​       (136)
Net cash flow used in financing activities      ​   ​          —   ​   ​     (1,928)   ​   ​     (1,841)
Net cash flow used in discontinued operations   ​   €   (45,316)   ​   €   (177,660)   ​   €   (193,072)
​
​
6. Segment informationWe currently operate as a single operating segment. 
GEOGRAPHICAL INFORMATION
In 2022, 2023 and 2024, our continuing operations were mainly located in Belgium, France, the Netherlands, Switzerland and United States. The revenues from our collaboration partner Gilead represented 87% of our total net revenues from continuing operations in 2024 (nearly 100% in 2023, 99.9% in 2022). The remaining 13% of the net revenues in 2024 consisted of supply revenues